Edesa Biotech (NASDAQ:EDSA) and Earth Science Tech (OTCMKTS:ETST) Head-To-Head Review

Edesa Biotech (NASDAQ:EDSA) and Earth Science Tech (OTCMKTS:ETST) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, valuation, risk, institutional ownership, analyst recommendations, earnings and profitability.

Analyst Ratings

This is a breakdown of recent ratings for Edesa Biotech and Earth Science Tech, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edesa Biotech	0	0	1	0	3.00
Earth Science Tech	0	0	0	0	0.00

Edesa Biotech currently has a consensus price target of $21.00, suggesting a potential upside of 809.09%. Given Edesa Biotech’s stronger consensus rating and higher possible upside, analysts clearly believe Edesa Biotech is more favorable than Earth Science Tech.

Volatility & Risk

Edesa Biotech has a beta of 0.6, indicating that its share price is 40% less volatile than the S&P 500. Comparatively, Earth Science Tech has a beta of 1.64, indicating that its share price is 64% more volatile than the S&P 500.

Profitability

This table compares Edesa Biotech and Earth Science Tech’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Edesa Biotech	N/A	-233.69%	-124.14%
Earth Science Tech	N/A	N/A	N/A

Institutional and Insider Ownership

5.5% of Edesa Biotech shares are owned by institutional investors. 25.0% of Edesa Biotech shares are owned by company insiders. Comparatively, 24.9% of Earth Science Tech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Edesa Biotech and Earth Science Tech”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edesa Biotech	N/A	N/A	-$6.17 million	($1.87)	-1.24
Earth Science Tech	$11.95 million	3.39	$810,000.00	N/A	N/A

Earth Science Tech has higher revenue and earnings than Edesa Biotech.

About Edesa Biotech

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of secretory phospholipase 2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.

About Earth Science Tech

Earth Science Tech, Inc. focuses on health and wellness industry. It operates men's health telemedicine platform under brand Peak name; and operates pharmacy. The company offers supplements and topicals products. The company was formerly known as Ultimate Novelty Sports, Inc. and changed its name to Earth Science Tech, Inc. in March 2014. Earth Science Tech, Inc. was incorporated in 2010 and is headquartered in Miami, Florida.